Press Releases Press Releases Keyword Search Year None202120202019201820172016201520142013 03 May '2021 French National Cancer Institute and XBiotech Join forces to Conduct Innovative Phase II/III Adaptive Multicenter Clinical Study for XBiotech’s New Cancer Drug for Colorectal Cancer 03 May '2021 French National Cancer Institute and XBiotech Join forces to Conduct Innovative Phase II/III Adaptive Multicenter Clinical Study for XBiotech’s New Cancer Drug for Colorectal Cancer 19 Apr '2021 FDA Gives Go-Ahead for XBiotech’s Candidate Therapy for Phase I/II Double-blind Placebo Controlled Study in Pancreatic Cancer 19 Apr '2021 FDA Gives Go-Ahead for XBiotech’s Candidate Therapy for Phase I/II Double-blind Placebo Controlled Study in Pancreatic Cancer 21 Jan '2021 XBiotech Candidate True Human™ COVID-19 Therapy Found to Target Highly Infectious Emerging Strain 19 Jan '2021 XBiotech Announces Cerebrovascular Medical Advisory Board & Development of New Stroke Therapy
Press Releases Keyword Search Year None202120202019201820172016201520142013 03 May '2021 French National Cancer Institute and XBiotech Join forces to Conduct Innovative Phase II/III Adaptive Multicenter Clinical Study for XBiotech’s New Cancer Drug for Colorectal Cancer 03 May '2021 French National Cancer Institute and XBiotech Join forces to Conduct Innovative Phase II/III Adaptive Multicenter Clinical Study for XBiotech’s New Cancer Drug for Colorectal Cancer 19 Apr '2021 FDA Gives Go-Ahead for XBiotech’s Candidate Therapy for Phase I/II Double-blind Placebo Controlled Study in Pancreatic Cancer 19 Apr '2021 FDA Gives Go-Ahead for XBiotech’s Candidate Therapy for Phase I/II Double-blind Placebo Controlled Study in Pancreatic Cancer 21 Jan '2021 XBiotech Candidate True Human™ COVID-19 Therapy Found to Target Highly Infectious Emerging Strain 19 Jan '2021 XBiotech Announces Cerebrovascular Medical Advisory Board & Development of New Stroke Therapy
03 May '2021 French National Cancer Institute and XBiotech Join forces to Conduct Innovative Phase II/III Adaptive Multicenter Clinical Study for XBiotech’s New Cancer Drug for Colorectal Cancer
03 May '2021 French National Cancer Institute and XBiotech Join forces to Conduct Innovative Phase II/III Adaptive Multicenter Clinical Study for XBiotech’s New Cancer Drug for Colorectal Cancer
19 Apr '2021 FDA Gives Go-Ahead for XBiotech’s Candidate Therapy for Phase I/II Double-blind Placebo Controlled Study in Pancreatic Cancer
19 Apr '2021 FDA Gives Go-Ahead for XBiotech’s Candidate Therapy for Phase I/II Double-blind Placebo Controlled Study in Pancreatic Cancer
21 Jan '2021 XBiotech Candidate True Human™ COVID-19 Therapy Found to Target Highly Infectious Emerging Strain
19 Jan '2021 XBiotech Announces Cerebrovascular Medical Advisory Board & Development of New Stroke Therapy
